Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD

Blood (2014) 124 (21): 293.

https://doi.org/10.1182/blood.V124.21.293.293

Published: 2014

Journal Articles

Predictors of Hospice Utilization Among Patients with Lymphoma

Oreofe O. Odejide, MD, Angel M. Cronin, MS, Ann LaCasce, MD, Gregory A. Abel, MD MPH

Blood (2014) 124 (21): 558.

https://doi.org/10.1182/blood.V124.21.558.558

Published: 2014

Journal Articles

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Ian Flinn, Nancy L. Bartlett, MD, Kristie A. Blum, MD, Kirit M Ardeshna, MD FRCPath, Ann LaCasce, MD, Christopher R. Flowers, MD, Andrei R. Shustov, MD, Kenneth Thress, PhD, Fred Zheng, MD PhD, Jeffery Skolnik, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 1725.

https://doi.org/10.1182/blood.V124.21.1725.1725

Published: 2014

Journal Articles

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, MD, Michelle Fanale, MD, Ann LaCasce, MD, Ariela Noy, Paolo Caimi, MD, Samir Parekh, MD, John W Hayslip, MD, Deepa Jagadeesh, MD MPH, Raymond S Lord, Mary J Lechowicz, MD, Rakesh Gaur, MD, Andrea Lucas, RN, Louis M Staudt, MD PhD, Seth M. Steinberg, PhD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Richard F Little, MPH, MD, Nancy L Bartlett, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 395.

https://doi.org/10.1182/blood.V124.21.395.395

Published: 2014

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Vicki A. Morrison, MD, Sin-Ho Jung, PhD, Jeffrey Johnson, MS, Ann LaCasce, MD, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD

Blood (2012) 120 (21): 3696.

https://doi.org/10.1182/blood.V120.21.3696.3696

Published: 2012

Journal Articles

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Jeffrey A. Barnes, MD, PhD, Kristen Stevenson, Ephraim P. Hochberg, MD, Tak Takvorian, MD, David C. Fisher, MD, Ann LaCasce, MD, Jennifer R. Brown, MD, PhD, Anuj K. Mahindra, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 3716.

https://doi.org/10.1182/blood.V118.21.3716.3716

Published: 2011

Journal Articles

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Lale Kostakoglu, MD, MPH, Heiko Schoder, MD, Nathan Hall, MD, PhD, David J. Straus, MD, Jeffrey L Johnson, PhD, Lawrence Schwartz, MD, Ann LaCasce, MD, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, George P. Canellos, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 3644.

https://doi.org/10.1182/blood.V118.21.3644.3644

Published: 2011

Journal Articles

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Andrew M. Evens, DO, MSc, Ann Vanderplas, M.S., Ann LaCasce, MD, MSc, Allison Crosby, MS, Auayporn Nademanee, M.D., Mark S. Kaminski, MD, Gregory A. Abel, MD, MPH, Michael Millenson, MD, Myron S. Czuczman, MD, Maria A. Rodriguez, MD, Joyce Niland, PhD, Andrew D Zelenetz, MD, PhD, Leo I. Gordon, MD, FACP, Jonathan Friedberg, MD

Blood (2011) 118 (21): 4112.

https://doi.org/10.1182/blood.V118.21.4112.4112

Published: 2011

Journal Articles

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Karim E Abou-Nassar, MD, Ann Vanderplas, Jonathan W. Friedberg, MD, Gregory Abel, MD, MPH, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Allison Crosby, MS, Leo I Gordon, MD, FACP, Andrew D Zelenetz, MD, Ann LaCasce, MD, MSc

Blood (2010) 116 (21): 81.

https://doi.org/10.1182/blood.V116.21.81.81

Published: 2010

Journal Articles

A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.

Jennifer R Brown, MD, PhD, Bradley Messmer, Lillian Werner, Evgeny Mikler, David C. Fisher, MD, Ann LaCasce, MD, MSc, Philippe Armand, MD, PhD, Eric D Jacobsen, MD, Virginia Dalton, Bethany Tesar, Stacey M Fernandes, Sean McDonough, MS, Jerome Ritz, MD, Laura Z Rassenti, PhD, Thomas J. Kipps, MD, PhD, Donna Neuberg, ScD, Arnold S. Freedman, MD

Blood (2010) 116 (21): 1381.

https://doi.org/10.1182/blood.V116.21.1381.1381

Published: 2010

Journal Articles

Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk

Philip C. Amrein, MD, Eyal C Attar, MD, Tak Takvorian, M.D., Ephraim Hochberg, Karen K Ballen, MD, Kathleen M Leahy, David C. Fisher, MD, Ann LaCasce, MD, MSc, Eric D Jacobsen, MD, Philippe Armand, MD, PhD, Robert Hasserjian, MD, Lillian Werner, Donna Neuberg, ScD, Jennifer R Brown, MD, PhD

Blood (2010) 116 (21): 2457.

https://doi.org/10.1182/blood.V116.21.2457.2457

Published: 2010

Journal Articles

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

Jia Ruan, MD, PhD, Peter Martin, Richard R Furman, MD, Julie M. Vose, MD, Ann LaCasce, MD, Ying-Kuen K. Cheung, PhD, Jennifer O'Loughlin, Rebecca Elstrom, MD, Ruben Niesvizky, MD, Amy Chadburn, MD, Scott Ely, MD, Ethel Cesarman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2009) 114 (22): 2682.

https://doi.org/10.1182/blood.V114.22.2682.2682

Published: 2009

Journal Articles

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, Owen A O'Connor, MD, PhD, Myron S Czuczman, Ann LaCasce, MD, John Gerecitano, MD, PhD, John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse

Blood (2009) 114 (22): 1711.

https://doi.org/10.1182/blood.V114.22.1711.1711

Published: 2009

Journal Articles

Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).

Ephraim P. Hochberg, MD, Nicole Birrer, Christiana E. Toomey, Jeffrey A. Barnes, M.D., Alfred Ian Lee, MD, Ann LaCasce, MD, Jeremy S. Abramson, MD

Blood (2009) 114 (22): 3755.

https://doi.org/10.1182/blood.V114.22.3755.3755

Published: 2009

Journal Articles

R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.

Ann LaCasce, MD, Jonathan L. Vandergrift, MS, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva M. Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn P. Nademanee, MD, Douglas W. Blayney, MD, Leo I. Gordon, MD, Michael Millenson, MD, Ann Vanderplas, Gregory A. Abel, MD, MPH, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD

Blood (2009) 114 (22): 403.

https://doi.org/10.1182/blood.V114.22.403.403

Published: 2009

Journal Articles

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Jonathan W. Friedberg, MD, Jeff Sharman, Julia Schaefer-Cutillo, Patrick B. Johnston, Sven De Vos, MD, PhD, Ann LaCasce, MD, John P. Leonard, MD, Larry D. Cripe, MD, Rajni Sinha, MD, Stephanie A. Gregory, John Sweetenham, Julie M. Vose, MD, Ann M Lowe, MD, R. Levy, Margaret A. Shipp, MD

Blood (2008) 112 (11): 3.

https://doi.org/10.1182/blood.V112.11.3.3

Published: 2008

Journal Articles

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, O. O’Connor, M.D., Myron S. Czuczman, MD, Ann LaCasce, MD, J. Gerecitano, M.D., Ph.D., John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Ph.D., Todd Busman, Ph.D., Raymond A. Knight, MBA, Sari Enschede, M.D., Andrew Krivoshik, M.D., Ph.D., Rod Humerickhouse, M.D., Ph.D

Blood (2008) 112 (11): 2108.

https://doi.org/10.1182/blood.V112.11.2108.2108

Published: 2008

Journal Articles

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

John P. Leonard, MD, Ann LaCasce, MD, Mitchell R Smith, MD, PhD, Ariela Noy, MD, Jeffrey T Yap, PhD, Annick D Van den Abbeele, MD, Jian Q Yu, MD, FRCPC, Selina Chen-Kiang, PhD, Scott A Ely, MD, PhD, Shankar Vallabhajosula, PhD, Lucian R Chirieac, MD, Steven M Larson, MD, Geoffrey I Shapiro, MD, PhD, Heiko Schoder

Blood (2008) 112 (11): 264.

https://doi.org/10.1182/blood.V112.11.264.264

Published: 2008

Journal Articles

High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.

Dan Zuckerman, MD, Ann Lacasce, MD, Eric Jacobsen, MD, Tak Takvorian, MD, Ephraim Hochberg, MD

Blood (2007) 110 (11): 2327.

https://doi.org/10.1182/blood.V110.11.2327.2327

Published: 2007

NARROW

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Predictors of Hospice Utilization Among Patients with Lymphoma

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.

Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk

CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.

Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only